NOVATO, California, September 13 /PRNewswire/ --

-Poster at Upcoming International Liver Cancer Conference

-Status of Ongoing Programs

-Regulatory Consulting Firm Retained

Raptor Pharmaceuticals Corp. ("Raptor" or the "Company") (OTC Bulletin
Board: RPTP.OB) announced today that Dr. Todd Zankel, the Company's Chief
Scientific Officer, will present a poster detailing promising preclinical
results from two preclinical studies of its HepTide(TM) liver targeting
program at the International Liver Cancer ("ILCA") Conference, to be held
October 5-7, 2007 in Barcelona, Spain.

Dr. Zankel's presentation will include an update on Raptor's liver
targeting platform based on human receptor-associated protein ("RAP"). For
more information on ILCA and the 2007 ILCA Conference, please visit
www.ilca-online.org. A synopsis of the poster will be available in the
investor relations section of Raptor's website at www.raptorpharma.com
shortly after Dr. Zankel presents at the conference.

Current Program Updates:

Investigational New Drug Application ("IND")-Enabling Studies Initiated
for HepTide(TM)

Based on promising results from ongoing preclinical studies of its RAP
liver targeting program, Raptor has initiated a pre-IND program for
HepTide(TM) (its liver targeting therapeutic conjugate using the RAP
targeting platform). The Company's goal is to file an IND for this
therapeutic conjugate with the Food and Drug Administration (the "FDA") by
the end of the second calendar quarter of 2008. To help execute this plan the
Company has retained Regulatory Professionals, Inc., a regulatory consulting
firm experienced in working with the FDA in all aspects of regulatory affairs
including preclinical and clinical support for pre- and post-approval
products, and preparation and submission of regulatory filings for marketing
approval.

Donna Kato, the CEO of Regulatory Professionals, Inc. stated, "We are
very excited to be working with Raptor as it advances toward clinical
trials."

Dr. Christopher Starr, Raptor's CEO stated, "Building an internal team of
high-quality individuals would take a great deal of time and money, while
Donna and her team provide us access to the best talent under a tight
development timeline and operational flexibility essential to an emerging
company." More information on Regulatory Professionals, Inc. can be found on
their website www.regprofessional.com.

In addition, Raptor has initiated proof-of-principle preclinical studies
targeting a new therapeutic area: the use of the HepTide delivery molecule to
enhance the distribution of antiviral drugs to the liver for the treatment of
viral hepatitis. HepTide has shown strong hepatotrophic activity by binding
selectively to liver cells or to infected liver cells in preclinical studies.
Conjugates of HepTide and antiviral agents could significantly improve
accumulation of these agents in the liver and reduce the amount of powerful
antiviral agents elsewhere in the body.

Stanford University Grant Renewed for NeuroTrans(TM) in Neurodegenerative
Diseases

Based on promising early results in blood-brain barrier ("BBB") transport
models from its collaboration initiated in August 2006, Raptor has renewed
its grant with Dr. William Mobley's neuroscience laboratory at Stanford
University. In the first year of the collaboration, a number of RAP peptides
were tested for their ability to cross the BBB. From these experiments, the
team selected a lead candidate transport peptide called RAP-2s. In this
second year, the team will continue to assess the bio-distribution of RAP-2s
within various brain compartments, commence testing of RAP-2s' ability to
deliver Nerve Growth Factor ("NGF") across the BBB, and to investigate the
potential for RAP-NGF conjugates to prevent or reverse neuronal injury in
preclinical models.

Preclinical Testing Completed for WntTide(TM) in Osteoporosis

Raptor has completed preclinical testing of WntTide, for its osteoporosis
program, utilizing Mesd and engineered Mesd-based peptides, and is awaiting
the final report of WntTide in a well-accepted preclinical model widely used
to test reduction in bone loss. WntTide may aid in increasing bone density in
the treatment of osteoporosis and rheumatoid arthritis. The Company has run
selected preclinical studies to move this program to a point where its
utility can be realistically assessed for further investment. If results are
positive, the Company plans to seek a collaborative arrangement with a
partner for further development of the peptide in this very widespread and
expensive disease. The Company licensed Mesd from Washington University, St.
Louis, for the treatment of osteoporosis and cancer in November 2006.

Scientific Publication Update

Raptor researchers published a paper entitled "Minimization of the third
domain of the LDL receptor-associated protein (RAP)," which describes their
efforts to develop a readily-manufactured RAP-based peptide to act as a
delivery vehicle to the liver. Raptor authors include Sara Isbell, Simone
Haslam and Dr. Todd Zankel. The Internet link to the paper, published by
Biochemical and Biophysical Research Communications dated September 28, 2007
in volume 361, issue 3, pages 758 to 762, will be posted in the Product
Programs, RAP section of our website www.raptorpharma.com.

About Raptor

Raptor Pharmaceuticals Corp.'s sole business is its 100% ownership of
Raptor Pharmaceutical Inc., a development stage biotechnology company which
bioengineers novel drugs and drug-targeting platforms derived from the human
receptor-associated protein ("RAP") and related proteins. The Company's
preclinical programs target cancer, neurodegenerative disorders, infectious
diseases and osteoporosis. HepTide(TM) utilizes engineered RAP-based peptides
conjugated to drugs to target their delivery to the liver. In
neurodegenerative diseases, engineered RAP peptides called NeuroTrans(TM) are
currently undergoing evaluation at Stanford University in cell culture and
preclinical models for their ability to enhance the transport of molecules
from blood to brain. In osteoporosis, Raptor is testing the ability of
WntTide, which are Mesd and engineered Mesd-based peptides and act through
LRP5, a known determinant of bone density, to combat osteoporosis and
increase bone density. In an effort to protect its novel approach, Raptor
currently has five patent applications in review in the U.S., and countries
in Europe and Asia, as well as two provisional patent applications licensed
from Washington University. In addition, the Company has recently submitted
two new provisional patent applications in the U.S., the first of which
covers a new family of RAP peptides, with the second application to further
support and expand the Company's coverage in specific disease indications.
For additional information, please visit www.raptorpharma.com.

FORWARD LOOKING STATEMENTS

This document contains forward-looking statements as that term is defined
in the Private Securities Litigation Reform Act of 1995. These statements
relate to future events, but are not limited to the ability of RAP to
conjugate to drugs or to target the liver, the ability of RAP peptides to
enhance the transport of molecules from blood to the brain, the ability of
Mesd or Mesd-based peptides to combat osteoporosis and increase bone density.
These statements are only predictions and involve known and unknown risks,
uncertainties and other factors, which may cause the Company's actual results
to be materially different from these forward-looking statements. Factors
which may significantly change or prevent the Company's forward looking
statements from fruition include that the Company may be unsuccessful in
developing any products; that its technology may not be validated as the
Company progresses further and its methods may not be accepted by the
scientific community; that the Company is unable to retain or attract key
employees whose knowledge is essential to the development of its products;
that unforeseen scientific difficulties develop with the Company's process;
that the Company's patents are not sufficient to protect essential aspects of
its technology; that competitors may invent better technology; that the
Company's products may not work as well as hoped or worse, that the Company's
products may harm recipients; and that the Company may not be able to raise
sufficient funds for development or working capital when required. As well,
the Company's products may never develop into useful products and even if
they do, they may not be approved for sale to the public. The Company
cautions readers not to place undue reliance on any such forward-looking
statements, which speak only as of the date they were made. Certain of these
risks, uncertainties, and other factors are described in greater detail in
the Company's filings from time to time with the Securities and Exchange
Commission ("SEC"), which we strongly urge you to read and consider,
including the Company's Registration Statement on Form SB-2, as amended, that
was declared effective on July 10, 2006, the Company's annual report on Form
10- KSB and Form 10-KSB/A filed with the SEC on November 22, 2006, and
January 18, 2007, respectively, and the Company's quarterly report Form
10-QSB filed with the SEC on June 29, 2007, all of which are available free
of charge on the SEC's web site at http://www.sec.gov.

Subsequent written and oral forward-looking statements attributable to
the Company or to persons acting on behalf of the Company are expressly
qualified in their entirety by the cautionary statements set forth in its
reports filed with the SEC. The Company expressly disclaims any intent or
obligation to update any forward-looking statements.

For more information, please contact:
    The Ruth Group
    Sara Ephraim (investors)
    +1-646-536-7002
    sephraim@theruthgroup.com

    Janine McCargo (media)
    +1-646-536-7033
    jmccargo@theruthgroup.com

    Web site: http://www.ilca-online.org
              http://www.raptorpharma.com
              http://www.regprofessional.com